Literature DB >> 16278972

Molecular pathogenesis of Parkinson's disease.

Sonia Gandhi1, Nicholas W Wood.   

Abstract

Parkinson's disease (PD) is a common and incurable neurodegenerative disease, affecting 1% of the population over the age of 65. Despite a well-described clinical and pathological phenotype, the molecular mechanisms which lead to neurodegeneration remain elusive. However, there is a wealth of evidence from both toxin based models and genetic based models, which suggest a major etiologic role for mitochondrial dysfunction, protein aggregation, the ubiquitin-proteasome system and kinase signalling pathways in the pathogenesis of PD. Ultimately, an understanding of the molecular events which precipitate neurodegeneration in idiopathic PD will enable the development of targeted and effective therapeutic strategies. We review the latest evidence for the proposed molecular processes and discuss their relevance to the pathogenesis of sporadic PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16278972

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  10 in total

1.  Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson's disease.

Authors:  Elizabeth A Sabens Liedhegner; Kelly M Steller; John J Mieyal
Journal:  Chem Res Toxicol       Date:  2011-08-22       Impact factor: 3.739

Review 2.  Mitochondria as a therapeutic target for aging and neurodegenerative diseases.

Authors:  P H Reddy; T P Reddy
Journal:  Curr Alzheimer Res       Date:  2011-06       Impact factor: 3.498

3.  Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine.

Authors:  April A Dukes; Victor S Van Laar; Michael Cascio; Teresa G Hastings
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

Review 4.  Redox imbalance in Parkinson's disease.

Authors:  Shankar J Chinta; Julie K Andersen
Journal:  Biochim Biophys Acta       Date:  2008-03-04

5.  Influence of PARP-1 polymorphisms in patients after traumatic brain injury.

Authors:  Ajit A Sarnaik; Yvette P Conley; David O Okonkwo; Taura L Barr; Ericka L Fink; Csaba Szabo; Patrick M Kochanek; Robert S B Clark
Journal:  J Neurotrauma       Date:  2010-03       Impact factor: 5.269

Review 6.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

7.  The S-nitrosylation status of PCNA localized in cytosol impacts the apoptotic pathway in a Parkinson's disease paradigm.

Authors:  Liang Yin; Yingying Xie; Songyue Yin; Xiaolei Lv; Jia Zhang; Zezong Gu; Haidan Sun; Siqi Liu
Journal:  PLoS One       Date:  2015-02-12       Impact factor: 3.240

Review 8.  P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes?

Authors:  Aleksandra Szybińska; Wiesława Leśniak
Journal:  Aging Dis       Date:  2017-07-21       Impact factor: 6.745

9.  An integrated pipeline for next-generation sequencing and annotation of mitochondrial genomes.

Authors:  Aaron R Jex; Ross S Hall; D Timothy J Littlewood; Robin B Gasser
Journal:  Nucleic Acids Res       Date:  2009-11-05       Impact factor: 16.971

10.  Identification of Genes Associated with Smad3-dependent Renal Injury by RNA-seq-based Transcriptome Analysis.

Authors:  Qin Zhou; Yuanyan Xiong; Xiao R Huang; Patrick Tang; Xueqing Yu; Hui Y Lan
Journal:  Sci Rep       Date:  2015-12-09       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.